Press & Events
Hyperion Therapeutics Added to NASDAQ Biotechnology Index (NBI)
Hyperion Therapeutics Drug Gets FDA Orphan Status
Source: Yahoo! NewsHyperion Therapeutics Receives Orphan Drug Exclusivity From FDA
Hyperion Therapeutics Issued Key Patent Pertaining to Use of Fasting Ammonia
Hyperion Therapeutics Receives New Coverage from Analysts at JMP Securities (HPTX)
Source: Utah People's PostHyperion finds new investor as 3i sells after double money
Source: City A.M. Active TraderHyperion Therapeutics Completes Follow-On Offering and Announces Exercise of Underwriters' Over-Allotment Option
Source: Nasdaq OMXHyperion Therapeutics Announces Pricing of Initial Public Offering
Hyperion Therapeutics Elects David W. Gryska to Board of Directors
Hyperion Therapeutics’ Glycerol Phenylbutyrate Meets Primary Endpoint in Phase III Pivotal Study in Urea Cycle Disorders
Archived Press
2013
AprilMarch
February
January
2012
DecemberNovember
October
September
August
July
June
May
April
March
February
January